{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T23:25:48Z","timestamp":1794957948976,"version":"4.9.1"},"reference-count":101,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,7]],"date-time":"2021-08-07T00:00:00Z","timestamp":1628294400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.biopha.2021.112020","type":"journal-article","created":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T01:21:43Z","timestamp":1628731303000},"page":"112020","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":121,"special_numbering":"C","title":["Advances in the treatment of Chagas disease: Promising new drugs, plants and targets"],"prefix":"10.1016","volume":"142","author":[{"given":"Paola","family":"Garc\u00eda-Huertas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Cardona-Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2021.112020_bib1","unstructured":"WHO, Chagas disease (American trypanosomiasis), 2021. \u3008https:\/\/www.who.int\/health-topics\/chagas-disease#tab=tab_1\u3009. (Accessed 26 April 2021)."},{"issue":"1","key":"10.1016\/j.biopha.2021.112020_bib2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0210156","article-title":"Prevalence of Chagas disease in Colombia: a systematic review and meta-analysis","volume":"14","author":"Olivera","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2021.112020_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/136793","article-title":"Globalization of Chagas disease: a growing concern in nonendemic countries","volume":"2012","author":"Klein","year":"2012","journal-title":"Epidemiol. Res. Int."},{"issue":"2","key":"10.1016\/j.biopha.2021.112020_bib4","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.idc.2012.03.002","article-title":"American trypanosomiasis (Chagas disease)","volume":"26","author":"Rassi","year":"2012","journal-title":"Infect. Dis. Clin. N. Am."},{"issue":"5","key":"10.1016\/j.biopha.2021.112020_bib5","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2174\/092986710790226101","article-title":"Chagas disease: progress and new perspectives","volume":"17","author":"S\u00e1nchez-Sancho","year":"2010","journal-title":"Curr. Med. Chem."},{"issue":"13","key":"10.1016\/j.biopha.2021.112020_bib6","doi-asserted-by":"crossref","first-page":"5022","DOI":"10.1073\/pnas.0711014105","article-title":"A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes","volume":"105","author":"Wilkinson","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"2","key":"10.1016\/j.biopha.2021.112020_bib7","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1093\/infdis\/jis331","article-title":"Benznidazole-resistance in Trypanosoma cruzi is a readily acquired trait that can arise independently in a single population","volume":"206","author":"Mejia","year":"2012","journal-title":"J. Infect. Dis."},{"issue":"1","key":"10.1016\/j.biopha.2021.112020_bib8","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1128\/AAC.05135-11","article-title":"Activation of benznidazole by trypanosomal type I nitroreductases results in glyoxal formation","volume":"56","author":"Hall","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"issue":"15","key":"10.1016\/j.biopha.2021.112020_bib9","doi-asserted-by":"crossref","first-page":"13088","DOI":"10.1074\/jbc.M111.230847","article-title":"Nifurtimox activation by trypanosomal type I nitroreductases generates cytotoxic nitrile metabolites","volume":"286","author":"Hall","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.biopha.2021.112020_bib10","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1590\/S0074-02762009000400002","article-title":"Present situation and new strategies for Chagas disease chemotherapy: a proposal","volume":"104","author":"Coura","year":"2009","journal-title":"Mem. Inst. Oswaldo Cruz"},{"issue":"5","key":"10.1016\/j.biopha.2021.112020_bib11","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/0035-9203(87)90020-4","article-title":"Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease","volume":"81","author":"Filardi","year":"1987","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"issue":"9","key":"10.1016\/j.biopha.2021.112020_bib12","article-title":"Sensibilidad al benzonidazol de cepas de Trypanosoma cruzi sugiere la circulaci\u00f3n de cepas naturalmente resistentes en Colombia","volume":"32","author":"Mej\u00eda-Jaramillo","year":"2012","journal-title":"Biomedica"},{"issue":"5","key":"10.1016\/j.biopha.2021.112020_bib13","first-page":"357","article-title":"[Clinico-therapeutic trial with benzonidazole in Chagas\u2019 disease]","volume":"18","author":"Ferreira","year":"1976","journal-title":"Rev. Inst. Med. Trop. Sao Paulo"},{"key":"10.1016\/j.biopha.2021.112020_bib14","first-page":"7","article-title":"Spontaneous dormancy protects","volume":"7","author":"S\u00e1nchez-Vald\u00e9z","year":"2018","journal-title":"Elife"},{"issue":"1","key":"10.1016\/j.biopha.2021.112020_bib15","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1177\/1087057114550585","article-title":"Chagas disease drug discovery: toward a new era","volume":"20","author":"Chatelain","year":"2015","journal-title":"J. Biomol. Screen."},{"issue":"2","key":"10.1016\/j.biopha.2021.112020_bib16","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1021\/acsinfecdis.8b00298","article-title":"Drug discovery for kinetoplastid diseases: future directions","volume":"5","author":"Rao","year":"2019","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.biopha.2021.112020_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.actatropica.2019.105107","article-title":"Drug discovery for chagas disease: a viewpoint","volume":"198","author":"Kratz","year":"2019","journal-title":"Acta Trop."},{"issue":"2","key":"10.1016\/j.biopha.2021.112020_bib18","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ijpddr.2014.02.002","article-title":"Drug repurposing and human parasitic protozoan diseases","volume":"4","author":"Andrews","year":"2014","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"issue":"14","key":"10.1016\/j.biopha.2021.112020_bib19","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1056\/NEJMoa1507574","article-title":"Randomized trial of benznidazole for chronic Chagas\u2019 cardiomyopathy","volume":"373","author":"Morillo","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2021.112020_bib20","unstructured":"DNDi, Drugs for Neglected Diseases Initiative Research and Development Portfolio 2020. New regimens and pediatric benznidazole. \u3008https:\/\/dndi.org\/research-development\/portfolio\/\u3009. (Accessed 20 July 2020)."},{"issue":"11","key":"10.1016\/j.biopha.2021.112020_bib21","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1371\/journal.pntd.0001870","article-title":"Fexinidazole: a potential new drug candidate for Chagas disease","volume":"6","author":"Bahia","year":"2012","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"8","key":"10.1016\/j.biopha.2021.112020_bib22","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1128\/AAC.02754-13","article-title":"Antitrypanosomal activity of fexinidazole metabolites, potential new drug candidates for Chagas disease","volume":"58","author":"Bahia","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.biopha.2021.112020_bib23","unstructured":"DNDi, Drugs for Neglected Diseases Initiative Research and Development Portfolio 2020. Fexinidazole. https:\/\/dndi.org\/research-development\/portfolio\/. (Accessed 22 July 2020)."},{"issue":"Suppl 1","key":"10.1016\/j.biopha.2021.112020_bib24","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1590\/S0074-02762009000900041","article-title":"Ergosterol biosynthesis and drug development for Chagas disease","volume":"104","author":"Urbina","year":"2009","journal-title":"Mem. Inst. Oswaldo Cruz"},{"issue":"1","key":"10.1016\/j.biopha.2021.112020_bib25","doi-asserted-by":"crossref","first-page":"133","DOI":"10.4269\/ajtmh.1998.59.133","article-title":"Treatment of chronic Chagas\u2019 disease with itraconazole and allopurinol","volume":"59","author":"Apt","year":"1998","journal-title":"Am. J. Trop. Med. Hyg."},{"issue":"9","key":"10.1016\/j.biopha.2021.112020_bib26","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1093\/jac\/dkt135","article-title":"Treatment of Chagas\u2019 disease with itraconazole: electrocardiographic and parasitological conditions after 20 years of follow-up","volume":"68","author":"Apt","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"issue":"1","key":"10.1016\/j.biopha.2021.112020_bib27","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1128\/AAC.47.1.223-230.2003","article-title":"Chemotherapy with benznidazole and itraconazole for mice infected with different Trypanosoma cruzi clonal genotypes","volume":"47","author":"Toledo","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.biopha.2021.112020_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0128707","article-title":"Benznidazole\/itraconazole combination treatment enhances anti-Trypanosoma cruzi activity in experimental Chagas disease","volume":"10","author":"Ass\u00edria Fontes Martins","year":"2015","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.biopha.2021.112020_bib29","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1128\/AAC.05785-11","article-title":"Preclinical monitoring of drug association in experimental chemotherapy of Chagas\u2019 disease by a new HPLC-UV method","volume":"56","author":"Moreira da Silva","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.biopha.2021.112020_bib30","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1590\/S0074-02761993000100023","article-title":"An experimental and clinical assay with ketoconazole in the treatment of Chagas disease","volume":"88","author":"Brener","year":"1993","journal-title":"Mem. Inst. Oswaldo Cruz"},{"issue":"6","key":"10.1016\/j.biopha.2021.112020_bib31","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1093\/jac\/45.6.819","article-title":"A combination of benznidazole and ketoconazole enhances efficacy of chemotherapy of experimental Chagas\u2019 disease","volume":"45","author":"Ara\u00fajo","year":"2000","journal-title":"J. Antimicrob. Chemother."},{"issue":"4","key":"10.1016\/j.biopha.2021.112020_bib32","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1093\/jac\/dks478","article-title":"Efficacy of voriconazole in a murine model of acute Trypanosoma cruzi infection","volume":"68","author":"Gulin","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.biopha.2021.112020_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.actatropica.2020.105606","article-title":"In vitro and in vivo activity of voriconazole and benznidazole combination on trypanosoma cruzi infection models","volume":"211","author":"Gulin","year":"2020","journal-title":"Acta Trop."},{"issue":"7","key":"10.1016\/j.biopha.2021.112020_bib34","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1128\/AAC.42.7.1771","article-title":"Antiproliferative effects and mechanism of action of SCH 56592 against Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies","volume":"42","author":"Urbina","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"issue":"8","key":"10.1016\/j.biopha.2021.112020_bib35","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1371\/journal.pntd.0002367","article-title":"Benznidazole and posaconazole in experimental Chagas disease: positive interaction in concomitant and sequential treatments","volume":"7","author":"Diniz Lde","year":"2013","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"20","key":"10.1016\/j.biopha.2021.112020_bib36","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1056\/NEJMoa1313122","article-title":"Randomized trial of posaconazole and benznidazole for chronic Chagas\u2019 disease","volume":"370","author":"Molina","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.biopha.2021.112020_bib37","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.jacc.2016.12.023","article-title":"Benznidazole and posaconazole in eliminating parasites in asymptomatic T. Cruzi carriers: the STOP-CHAGAS trial","volume":"69","author":"Morillo","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.biopha.2021.112020_bib38","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0924-8579(02)00273-X","article-title":"In vitro and in vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas disease","volume":"21","author":"Urbina","year":"2003","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"7","key":"10.1016\/j.biopha.2021.112020_bib39","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1128\/AAC.01742-09","article-title":"Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi","volume":"54","author":"Diniz Lde","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"10.1016\/j.biopha.2021.112020_bib40","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S1473-3099(17)30538-8","article-title":"Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial","volume":"18","author":"Torrico","year":"2018","journal-title":"Lancet Infect. Dis."},{"issue":"2","key":"10.1016\/j.biopha.2021.112020_bib41","first-page":"111","article-title":"Purine analogs as chemotherapeutic agents in leishmaniasis and American trypanosomiasis","volume":"118","author":"Marr","year":"1991","journal-title":"J. Lab. Clin. Med."},{"issue":"6","key":"10.1016\/j.biopha.2021.112020_bib42","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02264-18","article-title":"Synergic effect of allopurinol in combination with nitroheterocyclic compounds against Trypanosoma cruzi","volume":"63","author":"Mazzeti","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.biopha.2021.112020_bib43","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1179\/000349803125002751","article-title":"Itraconazole or allopurinol in the treatment of chronic American trypanosomiasis: the regression and prevention of electrocardiographic abnormalities during 9 years of follow-up","volume":"97","author":"Apt","year":"2003","journal-title":"Ann. Trop. Med. Parasitol."},{"issue":"1","key":"10.1016\/j.biopha.2021.112020_bib44","doi-asserted-by":"crossref","first-page":"58","DOI":"10.4269\/ajtmh.2007.76.58","article-title":"Specific treatment for Trypanosoma cruzi: lack of efficacy of allopurinol in the human chronic phase of Chagas disease","volume":"76","author":"Rassi","year":"2007","journal-title":"Am. J. Trop. Med. Hyg."},{"issue":"6","key":"10.1016\/j.biopha.2021.112020_bib45","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1097\/QCO.0b013e32834c630e","article-title":"Boron-based drugs as antiprotozoals","volume":"24","author":"Jacobs","year":"2011","journal-title":"Curr. Opin. Infect. Dis."},{"issue":"1","key":"10.1016\/j.biopha.2021.112020_bib46","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1093\/infdis\/jit420","article-title":"New, combined, and reduced dosing treatment protocols cure Trypanosoma cruzi infection in mice","volume":"209","author":"Bustamante","year":"2014","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.biopha.2021.112020_bib47","doi-asserted-by":"crossref","first-page":"4703","DOI":"10.1038\/srep04703","article-title":"Nitroheterocyclic compounds are more efficacious than CYP51 inhibitors against Trypanosoma cruzi: implications for Chagas disease drug discovery and development","volume":"4","author":"Moraes","year":"2014","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.biopha.2021.112020_bib48","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/17460441.2020.1681394","article-title":"Why hasn\u2019t there been more progress in new Chagas disease drug discovery?","volume":"15","author":"Vermelho","year":"2020","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.biopha.2021.112020_bib49","unstructured":"DNDi, Drugs for Neglected Diseases Initiative Research and Development Portfolio 2020. DNDi-6148. \u3008https:\/\/dndi.org\/research-development\/portfolio\/\u3009. (Accessed 24 July 2020)."},{"issue":"7619","key":"10.1016\/j.biopha.2021.112020_bib50","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/nature19339","article-title":"Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness","volume":"537","author":"Khare","year":"2016","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.biopha.2021.112020_bib51","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/0035-9203(91)90139-P","article-title":"Medicinal plants in tropical medicine. 1. Medicinal plants against protozoal diseases","volume":"85","author":"Phillipson","year":"1991","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"issue":"4","key":"10.1016\/j.biopha.2021.112020_bib52","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1039\/c0np00069h","article-title":"Natural products and Chagas\u2019 disease: a review of plant compounds studied for activity against Trypanosoma cruzi","volume":"28","author":"Izumi","year":"2011","journal-title":"Nat. Prod. Rep."},{"issue":"2\u20133","key":"10.1016\/j.biopha.2021.112020_bib53","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0378-8741(01)00346-4","article-title":"Antiprotozoal activities of Colombian plants","volume":"78","author":"Weniger","year":"2001","journal-title":"J. Ethnopharmacol."},{"issue":"3","key":"10.1016\/j.biopha.2021.112020_bib54","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.jep.2007.01.015","article-title":"Antiprotozoal and cytotoxic activities in vitro of Colombian Annonaceae","volume":"111","author":"Osorio","year":"2007","journal-title":"J. Ethnopharmacol."},{"issue":"4","key":"10.1016\/j.biopha.2021.112020_bib55","doi-asserted-by":"crossref","first-page":"552","DOI":"10.7705\/biomedica.v31i4.426","article-title":"Trypanocidal and cytotoxic activity of extracts of Colombian plants","volume":"31","author":"Valencia","year":"2011","journal-title":"Biomedica"},{"key":"10.1016\/j.biopha.2021.112020_bib56","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.actatropica.2013.12.008","article-title":"Cytotoxic, mutagenic and genotoxic evaluation of crude extracts and fractions from Piper jericoense with trypanocidal action","volume":"131","author":"Hamedt","year":"2014","journal-title":"Acta Trop."},{"key":"10.1016\/j.biopha.2021.112020_bib57","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.exppara.2018.04.009","article-title":"Activity in vitro and in vivo against Trypanosoma cruzi of a furofuran lignan isolated from Piper jericoense","volume":"189","author":"Garc\u00eda-Huertas","year":"2018","journal-title":"Exp. Parasitol."},{"issue":"2","key":"10.1016\/j.biopha.2021.112020_bib58","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1590\/S0074-02762010000200013","article-title":"Chemical composition and antiprotozoal activities of Colombian Lippia spp essential oils and their major components","volume":"105","author":"Escobar","year":"2010","journal-title":"Mem. Inst. Oswaldo Cruz"},{"issue":"5","key":"10.1016\/j.biopha.2021.112020_bib59","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1078\/0944-7113-00252","article-title":"Trypanocidal activity of extracts from Brazilian Atlantic Rain Forest plant species","volume":"10","author":"Pizzolatti","year":"2003","journal-title":"Phytomedicine"},{"issue":"1","key":"10.1016\/j.biopha.2021.112020_bib60","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1179\/2047773213Y.0000000120","article-title":"Potential therapeutic use of herbal extracts in trypanosomiasis","volume":"108","author":"Teixeira","year":"2014","journal-title":"Pathog. Glob. Health"},{"issue":"1","key":"10.1016\/j.biopha.2021.112020_bib61","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jep.2010.06.011","article-title":"Investigation of plant extracts in traditional medicine of the Brazilian Cerrado against protozoans and yeasts","volume":"131","author":"Albernaz","year":"2010","journal-title":"J. Ethnopharmacol."},{"issue":"11","key":"10.1016\/j.biopha.2021.112020_bib62","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.phymed.2015.07.004","article-title":"In vitro and in vivo antiparasitic activity of Physalis angulata L. concentrated ethanolic extract against Trypanosoma cruzi","volume":"22","author":"Meira","year":"2015","journal-title":"Phytomedicine"},{"key":"10.1016\/j.biopha.2021.112020_bib63","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.biopha.2017.11.121","article-title":"The chemical composition and trypanocidal activity of volatile oils from Brazilian Caatinga plants","volume":"96","author":"Oliveira de Souza","year":"2017","journal-title":"Biomed. Pharmacother."},{"issue":"2","key":"10.1016\/j.biopha.2021.112020_bib64","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.exppara.2012.06.003","article-title":"Trypanocidal and cytotoxic activities of essential oils from medicinal plants of Northeast of Brazil","volume":"132","author":"Borges","year":"2012","journal-title":"Exp. Parasitol."},{"key":"10.1016\/j.biopha.2021.112020_bib65","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.actatropica.2014.04.006","article-title":"Anti-Trypanosoma cruzi activity of 10 medicinal plants used in northeast Mexico","volume":"136","author":"Molina-Garza","year":"2014","journal-title":"Acta Trop."},{"issue":"1","key":"10.1016\/j.biopha.2021.112020_bib66","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00436-011-2447-8","article-title":"In vitro and in vivo trypanocidal activity of native plants from the Yucatan Peninsula","volume":"110","author":"Polanco-Hern\u00e1ndez","year":"2012","journal-title":"Parasitol. Res."},{"issue":"7","key":"10.1016\/j.biopha.2021.112020_bib67","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1248\/bpb.28.1314","article-title":"Trypanocidal constituents in plants 5. Evaluation of some Mexican plants for their trypanocidal activity and active constituents in the seeds of Persea americana","volume":"28","author":"Abe","year":"2005","journal-title":"Biol. Pharm. Bull."},{"issue":"10","key":"10.1016\/j.biopha.2021.112020_bib68","doi-asserted-by":"crossref","first-page":"12621","DOI":"10.3390\/molecules181012621","article-title":"Assessment of the anti-protozoal activity of crude Carica papaya seed extract against Trypanosoma cruzi","volume":"18","author":"Jim\u00e9nez-Coello","year":"2013","journal-title":"Molecules"},{"issue":"9","key":"10.1016\/j.biopha.2021.112020_bib69","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1248\/bpb.25.1188","article-title":"Trypanocidal constituents in plants 1. Evaluation of some Mexican plants for their trypanocidal activity and active constituents in Guaco, roots of Aristolochia taliscana","volume":"25","author":"Abe","year":"2002","journal-title":"Biol. Pharm. Bull."},{"issue":"4","key":"10.1016\/j.biopha.2021.112020_bib70","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/s00436-005-0060-4","article-title":"In vitro evaluation of trypanocidal activity in plants used in Argentine traditional medicine","volume":"98","author":"S\u00fclsen","year":"2006","journal-title":"Parasitol. Res."},{"key":"10.1016\/j.biopha.2021.112020_bib71","first-page":"1","article-title":"Trypanocidal activity of South American Vernonieae (Asteraceae) extracts and its sesquiterpene lactones","author":"Sosa","year":"2020","journal-title":"Nat. Prod. Res."},{"issue":"10","key":"10.1016\/j.biopha.2021.112020_bib72","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.3109\/13880209.2016.1150304","article-title":"Trypanocidal and leishmanicidal activities of flavonoids isolated from Stevia satureiifolia var. satureiifolia","volume":"54","author":"Beer","year":"2016","journal-title":"Pharm. Biol."},{"key":"10.1016\/j.biopha.2021.112020_bib73","doi-asserted-by":"crossref","DOI":"10.1100\/2012\/121253","article-title":"In vitro evaluation of antiprotozoal and antiviral activities of extracts from Argentinean Mikania species","volume":"2012","author":"Laurella","year":"2012","journal-title":"Scientific World J."},{"key":"10.1016\/j.biopha.2021.112020_bib74","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/627898","article-title":"Trypanocidal activity of Smallanthus sonchifolius: identification of active sesquiterpene lactones by bioassay-guided fractionation","volume":"2013","author":"Frank","year":"2013","journal-title":"Evid. Based Complement. Altern. Med."},{"issue":"1","key":"10.1016\/j.biopha.2021.112020_bib75","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1186\/s13071-017-2509-6","article-title":"Germacranolide-type sesquiterpene lactones from Smallanthus sonchifolius with promising activity against Leishmania mexicana and Trypanosoma cruzi","volume":"10","author":"Ulloa","year":"2017","journal-title":"Parasit. Vectors"},{"issue":"5\u20136","key":"10.1016\/j.biopha.2021.112020_bib76","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1515\/znc-2013-5-605","article-title":"Medicinal plants of Chile: evaluation of their anti-Trypanosoma cruzi activity","volume":"68","author":"Mu\u00f1oz","year":"2013","journal-title":"Z. Naturforschung C J. Biosci."},{"issue":"5","key":"10.1016\/j.biopha.2021.112020_bib77","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3109\/13880200903193344","article-title":"Screening of Latin American plants for antiparasitic activities against malaria, Chagas disease, and leishmaniasis","volume":"48","author":"Calder\u00f3n","year":"2010","journal-title":"Pharm. Biol."},{"issue":"10","key":"10.1016\/j.biopha.2021.112020_bib78","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.2174\/156802611795429185","article-title":"Target validation: linking target and chemical properties to desired product profile","volume":"11","author":"Wyatt","year":"2011","journal-title":"Curr. Top. Med. Chem."},{"issue":"13","key":"10.1016\/j.biopha.2021.112020_bib79","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.2174\/0929867311320130004","article-title":"Polypharmacology in a single drug: multitarget drugs","volume":"20","author":"Bolognesi","year":"2013","journal-title":"Curr. Med. Chem."},{"issue":"2","key":"10.1016\/j.biopha.2021.112020_bib80","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.tips.2007.11.007","article-title":"Novel paradigms for drug discovery: computational multitarget screening","volume":"29","author":"Jenwitheesuk","year":"2008","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.biopha.2021.112020_bib81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jmgm.2014.02.006","article-title":"In silico investigation of medicinal spectrum of imidazo-azines from the perspective of multitarget screening against malaria, tuberculosis and Chagas disease","volume":"50","author":"Kumar","year":"2014","journal-title":"J. Mol. Graph. Model."},{"issue":"3\u20134","key":"10.1016\/j.biopha.2021.112020_bib82","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.exppara.2004.03.006","article-title":"The glycosome membrane of Trypanosoma cruzi epimastigotes: protein and lipid composition","volume":"106","author":"Qui\u00f1ones","year":"2004","journal-title":"Exp. Parasitol."},{"key":"10.1016\/j.biopha.2021.112020_bib83","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/B978-0-12-385863-4.00004-6","article-title":"Targeting Trypanosoma cruzi sterol 14\u03b1-demethylase (CYP51)","volume":"75","author":"Lepesheva","year":"2011","journal-title":"Adv. Parasitol."},{"key":"10.1016\/j.biopha.2021.112020_bib84","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3389\/fcimb.2018.00439","article-title":"Discovery and genetic validation of chemotherapeutic targets for Chagas\u2019 disease","volume":"8","author":"Osorio-M\u00e9ndez","year":"2018","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"11","key":"10.1016\/j.biopha.2021.112020_bib85","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.2174\/0929867323666161227094049","article-title":"Trypanothione reductase and superoxide dismutase as current drug targets for Trypanosoma cruzi: an overview of compounds with activity against Chagas disease","volume":"24","author":"Beltran-Hortelano","year":"2017","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.biopha.2021.112020_bib86","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1146\/annurev.mi.46.100192.003403","article-title":"Metabolism and functions of trypanothione in the Kinetoplastida","volume":"46","author":"Fairlamb","year":"1992","journal-title":"Annu. Rev. Microbiol."},{"issue":"1","key":"10.1016\/j.biopha.2021.112020_bib87","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1517\/14728220802623881","article-title":"Trypanosoma cruzi targets for new chemotherapeutic approaches","volume":"13","author":"Soeiro","year":"2009","journal-title":"Expert Opin. Ther. Targets"},{"issue":"5\u20136","key":"10.1016\/j.biopha.2021.112020_bib88","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/0891-5849(88)90109-8","article-title":"Superoxide dismutase: the first twenty years (1968-1988)","volume":"5","author":"McCord","year":"1988","journal-title":"Free Radic. Biol. Med."},{"issue":"2","key":"10.1016\/j.biopha.2021.112020_bib89","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.cbpa.2004.02.011","article-title":"Superoxide dismutases: active sites that save, but a protein that kills","volume":"8","author":"Miller","year":"2004","journal-title":"Curr. Opin. Chem. Biol."},{"issue":"2","key":"10.1016\/j.biopha.2021.112020_bib90","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.freeradbiomed.2005.06.021","article-title":"The presence of four iron-containing superoxide dismutase isozymes in trypanosomatidae: characterization, subcellular localization, and phylogenetic origin in Trypanosoma brucei","volume":"40","author":"Dufernez","year":"2006","journal-title":"Free Radic. Biol. Med."},{"issue":"12","key":"10.1016\/j.biopha.2021.112020_bib91","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.2174\/1381612013397528","article-title":"The major cysteine proteinase of Trypanosoma cruzi: a valid target for chemotherapy of Chagas disease","volume":"7","author":"Jose Cazzulo","year":"2001","journal-title":"Curr. Pharm. Des."},{"issue":"Pt 3","key":"10.1016\/j.biopha.2021.112020_bib92","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1242\/jcs.96.3.485","article-title":"Cysteine proteinase in Trypanosoma cruzi: immunocytochemical localization and involvement in parasite-host cell interaction","volume":"96","author":"Souto-Padr\u00f3n","year":"1990","journal-title":"J. Cell Sci."},{"issue":"1","key":"10.1016\/j.biopha.2021.112020_bib93","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.bbapap.2011.05.011","article-title":"The peptidases of Trypanosoma cruzi: digestive enzymes, virulence factors, and mediators of autophagy and programmed cell death","volume":"1824","author":"Alvarez","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.biopha.2021.112020_bib94","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.565142","article-title":"Cruzipain and its physiological inhibitor, chagasin, as a DNA-based therapeutic vaccine against","volume":"11","author":"Cerny","year":"2020","journal-title":"Front. Immunol."},{"issue":"13","key":"10.1016\/j.biopha.2021.112020_bib95","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1096\/fasebj.7.13.8405811","article-title":"Trans-sialidase: a unique enzyme activity discovered in the protozoan Trypanosoma cruzi","volume":"7","author":"Colli","year":"1993","journal-title":"FASEB J."},{"issue":"7","key":"10.1016\/j.biopha.2021.112020_bib96","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S0169-4758(00)01698-7","article-title":"Functional diversity in the trans-sialidase and mucin families in Trypanosoma cruzi","volume":"16","author":"Frasch","year":"2000","journal-title":"Parasitol. Today"},{"issue":"7","key":"10.1016\/j.biopha.2021.112020_bib97","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/0092-8674(91)90008-M","article-title":"A novel cell surface trans-sialidase of Trypanosoma cruzi generates a stage-specific epitope required for invasion of mammalian cells","volume":"65","author":"Schenkman","year":"1991","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.biopha.2021.112020_bib98","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1093\/glycob\/cwv057","article-title":"The trans-sialidase, the major Trypanosoma cruzi virulence factor: three decades of studies","volume":"25","author":"Freire-de-Lima","year":"2015","journal-title":"Glycobiology"},{"issue":"3","key":"10.1016\/j.biopha.2021.112020_bib99","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0163-7258(03)00071-8","article-title":"Potential chemotherapeutic targets in the purine metabolism of parasites","volume":"99","author":"el Kouni","year":"2003","journal-title":"Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.biopha.2021.112020_bib100","doi-asserted-by":"crossref","first-page":"74","DOI":"10.2174\/1574891X11666161024165304","article-title":"Targets and patented drugs for chemotherapy of Chagas disease in the last 15 years-period","volume":"11","author":"Duschak","year":"2016","journal-title":"Recent Pat. Antiinfect. Drug Discov."},{"key":"10.1016\/j.biopha.2021.112020_bib101","article-title":"Ubiquitination and the proteasome as drug targets in trypanosomatid diseases","volume":"8","author":"Bijlmakers","year":"2020","journal-title":"Front. Chem."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221008039?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221008039?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T12:31:39Z","timestamp":1760099499000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332221008039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":101,"alternative-id":["S0753332221008039"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2021.112020","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in the treatment of Chagas disease: Promising new drugs, plants and targets","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2021.112020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"112020"}}